Complement gene expression by rabbit heart: Upregulation by ischemia and reperfusion

Circulation Research

Volumn 82, Issue 11, 1998, Pages 1224-1230

  Yasojima, Koji ^a   Kilgore, Kenneth S ^b   Washington, Ruth A ^b   Lucchesi, Benedict R ^b   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Brain; Complement C3; Complement C9; Liver; Myocardial infarction; Spleen

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9;

ANIMAL TISSUE; ARTICLE; CELL DAMAGE; COMPLEMENT ACTIVATION; CORONARY ARTERY BLOOD FLOW; GENE EXPRESSION REGULATION; GENETIC COMPLEMENTATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032526372     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.11.1224     Document Type: Article

References (49)

1. Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke. 1993;24(suppl I):I-41-I-47.
2. 2+ on the lytic process. J Immunol. 1987;138:1530-1536.
3. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989;264:1-14.
4. Berger HJ, Taratuska A, Smith TW, Halperin JA. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Am J Physiol. 1993;265:267-272.
5. Nicolson-Weller A, Happerin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res. 1993;12:244-257.
6. Niculescu F, Rus H, Shin MI. Receptor-independent acjivation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem. 1994;269:4417-4423.
7. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1 : in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
8. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart: role of the terminal complement components. Circ Res. 1992;71:303-319.
9. Schafer H, Malhey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945-1949.
10. Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S. Early accumulation of the terminal complement-complex in the ischaemie myocardium after reperfusion. Eur Heart J. 1994;15:418-423.
11. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
12. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, Becker P, Darius H, Rupprecht HJ, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of Cl esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701-708.
13. Murohara, T, Quo JP, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol. 1995;17:499-507.
14. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448-H457.
15. Smith EF III, Griswold DE, Egan JW, Hillegass LM, Smith RA, Hibbs MJ, Gagnon RC. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1. Eur J Pharmacol. 1993;236:477-481.
16. Shandelya SM, Kuppusamy P, Hershowitz A, Weisfeldt ML, Zweier JL. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart: evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation. 1993;88:2812-2826.
17. Ito W, Schafer HJ, Bhakdi S, Klask R, Hansen S, Schaarschmidt S, Schofer J, Hugo F, Hamdoch T, Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res. 1996;32:294-305.
18. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95-105.
19. Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H. The complement system in ischemic heart disease. Circulation. 1990;81:156-163.
20. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol. 1993;143:65-75,
21. Tada T, Okada H, Okada N, Tateyama H, Suzuki H, Takahashi Y, Eimoto T. Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. Virchows Arch. 1997;430:327-332.
22. Lagrand WK, Niessen HWM, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FWA, Meijer CJL, Hack CE. C-Reactive protein colocalized with complement in human hearts during acute myocardial infarction. Circulation. 1997;97:97-103.
23. Kilgore KS, Friedrichs GS, Johnson CR, Schasteen CS, Riley DP, Weiss RH, Ryan U, Lucchesi BR. Protective effects of the SOD-mimetic SC-52608 against ischemia reperfusion damage in the rabbit isolated heart. J Mol Cell Cardiol. 1994;26:995-1006.
24. Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer brain. Brain Res. 1997;769:385-390.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall EJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
27. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols. San Diego, Calif: Academic Press; 1990:3-12.
28. Kusano M, Choi N-H, Tomita M, Yamamoto K, Migita S, Sekiya T, Nishimura S. Nucleotide sequence of cDNA and derived amino acid sequence of rabbit complement component C3 a-chain. Immunol Invest. 1986;15:365-378.
29. Huesler T, Lockert DH, Kaufman KM, Sodetz JM, Sims PJ. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59. J Biol Chem. 1995;270:3483-3486.
30. Haendler B, Hofer-Warbinek R, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J. 1987;6:947-950.
31. Danielson PE, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, Sutcliffe JG. p1B15: A cDNA clone of the rat mRNA encoding cyclophilin. DNA. 1988;7:261-267.
32. Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391-395.
33. Gulati P, Guc D, Lemercier C, Lappin D, Whaley K. Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium. Rheumatol Int. 1994;14:13-19.
34. Lappin DF, Guc D, Hill A, McShane T, Whaley K. Effect of interferon-g on complement expression in different cell types. Biochem J. 1992;281:437-442.
35. Gasque P, Fontaine M, Morgan BP. Complement expression in human brain: biosynthesis of terminal pathway components and regulators in human glial cells and cell lines, J Immunol. 1995;154:4726-4733.
36. Rus HG, Kim LM, Niculescu Fl, Shin ML. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus. J Immunol. 1992;148:928-933.
37. Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglia derived from postmortem human brain. J Neurosci Res. 1995;40:478-493.
38. Gasque P, Ischenko A, Legoedee J, Mauger C, Schouft M-T, Fontaine M. Expression of the classical complement pathway by human gliomas in culture. J Biol Chem. 1993;268:25068-25074.
39. Walker DC, McGeer PL. Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin. Neurosci Lett. 1993;157:99-102.
40. Johnson E, Hetland G. Mononuclear phagocytes have the potential to synthesize the complete functional complement system. Scand J Immunol. 1988;27:489-493.
41. Katz Y, Strunk RC. Synovial fibroblast-like cells synthesize seven proteins of the complement system. Arthritis Rheum. 1988;31:1365-1370.
42. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neural Sci. 1989;16:516-527.
43. DeCeulaer C, Papazoglou S, Whaley K. Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and synovial fluid membrane cells from patients with rheumatoid arthritis. Immunology. 1980;41:37-43.
44. Rus HG, Niculescu F, Vlaicu R. Presence of C5b-9 complement complex and S-protein in infarcted areas with necrosis and sclerosis. Immunol Lett. 1987;16:15-20.
45. Hugo F, Hamdoch T, Mathey D, Schafer H, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132-136.
46. Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RD. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human Clq and fix complement. Circ Res. 1989;64:607-615.
47. Beyersdorf F, Allen BS, Buckberg GD, Acar C, Okamoto F, Sjostrand F, Young HH, Bugyi HI, Studies on prolonged acute regional ischemia. I: evidence for preserved cellular viability after 6 hours of coronary occlusion. J Thorac Cardiovasc Surg. 1989;98:112-126.
48. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998;97:795-804.
49. Gralinski MR, Park JL, Ozeck MA, Wiater BC, Lucchesi BR. LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart. J Pharmacol Exp Ther. 1997;282:554-560.